These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22797736)

  • 1. PEPFAR's evolving HIV prevention approaches for key populations--people who inject drugs, men who have sex with men, and sex workers: progress, challenges, and opportunities.
    Needle R; Fu J; Beyrer C; Loo V; Abdul-Quader AS; McIntyre JA; Li Z; Mbwambo JK; Muthui M; Pick B
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S145-51. PubMed ID: 22797736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief.
    Chi BH; Adler MR; Bolu O; Mbori-Ngacha D; Ekouevi DK; Gieselman A; Chipato T; Luo C; Phelps BR; McClure C; Mofenson LM; Stringer JS
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3(Suppl 3):S78-87. PubMed ID: 22797744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond indicators: advances in global HIV monitoring and evaluation during the PEPFAR era.
    Porter LE; Bouey PD; Curtis S; Hochgesang M; Idele P; Jefferson B; Lemma W; Myrick R; Nuwagaba-Biribonwoha H; Prybylski D; Souteyrand Y; Tulli T
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S120-6. PubMed ID: 22797733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expanding role of civil society in the global HIV/AIDS response: what has the President's Emergency Program For AIDS Relief's role been?
    Coutinho A; Roxo U; Epino H; Muganzi A; Dorward E; Pick B
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S152-7. PubMed ID: 22797737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of sexually transmitted HIV infections through the President's Emergency Plan for AIDS Relief: a history of achievements and lessons learned.
    Ryan CA; Conly SR; Stanton DL; Hasen NS
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S70-7. PubMed ID: 22797743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEPFAR, health system strengthening, and promoting sustainability and country ownership.
    Palen J; El-Sadr W; Phoya A; Imtiaz R; Einterz R; Quain E; Blandford J; Bouey P; Lion A
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S113-9. PubMed ID: 22797732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEPFAR support for the scaling up of collaborative TB/HIV activities.
    Howard AA; Gasana M; Getahun H; Harries A; Lawn SD; Miller B; Nelson L; Sitienei J; Coggin WL
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3(0 3):S136-44. PubMed ID: 22797735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voluntary medical male circumcision: an HIV prevention priority for PEPFAR.
    Reed JB; Njeuhmeli E; Thomas AG; Bacon MC; Bailey R; Cherutich P; Curran K; Dickson K; Farley T; Hankins C; Hatzold K; Justman J; Mwandi Z; Nkinsi L; Ridzon R; Ryan C; Bock N
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3(0 3):S88-95. PubMed ID: 22797745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Countries where HIV is concentrated among most-at-risk populations get disproportionally lower funding from PEPFAR.
    Grosso AL; Tram KH; Ryan O; Baral S
    Health Aff (Millwood); 2012 Jul; 31(7):1519-28. PubMed ID: 22778341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saving lives for a lifetime: supporting orphans and vulnerable children impacted by HIV/AIDS.
    Nyberg BJ; Yates DD; Lovich R; Coulibaly-Traore D; Sherr L; Thurman TR; Sampson A; Howard B
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3():S127-35. PubMed ID: 22797734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEPFAR scale-up of pediatric HIV services: innovations, achievements, and challenges.
    Abrams EJ; Simonds RJ; Modi S; Rivadeneira E; Vaz P; Kankasa C; Tindyebwa D; Phelps BR; Bowsky S; Teasdale CA; Koumans E; Ruff AJ
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3(Suppl 3):S105-12. PubMed ID: 22797731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key Population Hotspots in Nigeria for Targeted HIV Program Planning: Mapping, Validation, and Reconciliation.
    Lo J; Nwafor SU; Schwitters AM; Mitchell A; Sebastian V; Stafford KA; Ezirim I; Charurat M; McIntyre AF
    JMIR Public Health Surveill; 2021 Feb; 7(2):e25623. PubMed ID: 33616537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scale-up of HIV treatment through PEPFAR: a historic public health achievement.
    El-Sadr WM; Holmes CB; Mugyenyi P; Thirumurthy H; Ellerbrock T; Ferris R; Sanne I; Asiimwe A; Hirnschall G; Nkambule RN; Stabinski L; Affrunti M; Teasdale C; Zulu I; Whiteside A
    J Acquir Immune Defic Syndr; 2012 Aug; 60 Suppl 3(Suppl 3):S96-104. PubMed ID: 22797746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability and Quality of Surveillance and Survey Data on HIV Prevalence Among Sex Workers, Men Who Have Sex With Men, People Who Inject Drugs, and Transgender Women in Low- and Middle-Income Countries: Review of Available Data (2001-2017).
    Arias Garcia S; Chen J; Calleja JG; Sabin K; Ogbuanu C; Lowrance D; Zhao J
    JMIR Public Health Surveill; 2020 Nov; 6(4):e21688. PubMed ID: 33200996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the impact of the US President's Emergency Plan for AIDS Relief on HIV treatment and prevention programmes in Africa.
    Heaton LM; Bouey PD; Fu J; Stover J; Fowler TB; Lyerla R; Mahy M
    Sex Transm Infect; 2015 Dec; 91(8):615-20. PubMed ID: 26056389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ghana's HIV epidemic and PEPFAR's contribution towards epidemic control.
    Ali H; Amoyaw F; Baden D; Durand L; Bronson M; Kim A; Grant-Greene Y; Imtiaz R; Swaminathan M
    Ghana Med J; 2019 Mar; 53(1):59-62. PubMed ID: 31138945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of community outreach HIV prevention programs in Vietnam: a mixed methods evaluation.
    Sabin LL; Semrau K; DeSilva M; Le LTT; Beard JJ; Hamer DH; Tuchman J; Hammett TM; Halim N; Reuben M; Mesic A; Vian T
    BMC Public Health; 2019 Aug; 19(1):1130. PubMed ID: 31420034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating prevalence and modelling correlates of HIV test positivity among female sex workers, men who have sex with men, people who inject drugs, transgender people and prison inmates in Sierra Leone, 2021.
    Dwomoh D; Wurie I; Harding Y; Sedzro KM; Kandeh J; Tagoe H; Addo C; Arhinful DK; Sessay ARC; Kamara JL; Mansaray K; Ampofo WK
    AIDS Res Ther; 2023 Sep; 20(1):70. PubMed ID: 37759241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of HIV Preexposure Prophylaxis to 35 PEPFAR-Supported Early Program Adopters, October 2016-September 2018.
    Djomand G; Bingham T; Benech I; Muthui M; Savva H; Alamo S; Manopaiboon C; Wheeler T; Mital S
    MMWR Morb Mortal Wkly Rep; 2020 Feb; 69(8):212-215. PubMed ID: 32107367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.